BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Sun Pharma reportsÂ India sales at Rs 103,432 M for FY20-21

27 May 2021 | News

The EBITDA was at Rs 19,568 million, up by 55.8 per cent over Q4 last year



Sun Pharmaceutical Industries has reported financials for the fourth quarter and full-year ending March 31, 2021.

In Q4FY21, the consolidated sales from operations at Rs 84,314 million, growth of 4.4 per cent over Q4 last year. The India sales at Rs 26,709 million, a growth of 12.9 per cent compared to Q4 last year.

The R&D investments were at Rs 5,571 million (6.6 per cent of sales) compared to Rs 5,360 million (6.6 per cent of sales) for Q4FY20. The EBITDA was at Rs 19,568 million, up by 55.8 per cent over Q4 last year, with a resulting EBITDA margin of 23.2 per cent.

The adjusted net profit for the quarter was at Rs 13,430.7 million, up by 103.3 per cent YoY, after excluding the exceptional items of Rs. 6,728.1 million, the exceptional tax item of Rs 1,212.3 million and relevant minority interest of Rs 1,026.6 million. The reported net profit for Q4FY21 was at Rs 8,941.5 million, up 124 per cent over Q4 last year.

The full-year FY21 consolidated financials states that the consolidated sales from operations were at Rs 331,392 million, up by 2.5 per cent over the same period last year. India sales were at Rs 103,432 million, up by 6.5 per cent over the same period last year.

The adjusted net profit for the year was at Rs 59,317.8 million, up by 47.4 per cent YoY, after excluding the exceptional items of Rs 43,061.4 million, the exceptional tax item of Rs 4,095.1 million and relevant minority interest of Rs 8,686.7 million. The reported net profit for FY21 was at Rs 29,038.2 million, lower by 23 per cent over last year.

Dilip Shanghvi, Managing Director, Sun Pharma said, “FY21 was a year marked by a highly volatile business environment due to the global Covid-19 pandemic and lockdowns in various countries. Despite these challenges, I am happy to see that we have been able to maintain business continuity and record positive overall growth. While our India business continues to outperform the average industry growth, our global speciality sales have continued to show an improving trend. Global Ilumya sales for the year have grown by 51 per cent to $143 million.”